Adverse drug reactions resulting in hyperthermia in the intensive care unit

Critical Care Medicine

Volumn 38, Issue 6 SUPPL., 2010, Pages

  McAllen, Karen J ^a   Schwartz, David R ^b  

^a SPECTRUM HEALTH   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Baclofen; Cyproheptadine; Dantrolene; Fever; Hyperthermia; Malignant; Neuroleptic; Serotonin; Temperature

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ACETYLCHOLINE; ADRENERGIC RECEPTOR BLOCKING AGENT; ALKALOID; ALKALOID DERIVATIVE; AMPHETAMINE DERIVATIVE; ANTIHISTAMINIC AGENT; ANTIPARKINSON AGENT; ATROPINE; BACLOFEN; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR; DANTROLENE; DOPAMINE RECEPTOR; DROPERIDOL; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NEUROPEPTIDE; NORADRENALIN; PHENYLEPHRINE; PROSTAGLANDIN; RYANODINE RECEPTOR 1; SCOPOLAMINE; SEDATIVE AGENT; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; SUXAMETHONIUM; UNINDEXED DRUG;

AUTONOMIC DYSFUNCTION; CASE STUDY; CEREBRAL PALSY; DELIRIUM; DIFFERENTIAL DIAGNOSIS; DRUG FATALITY; DRUG FEVER; DRUG WITHDRAWAL; EARLY DIAGNOSIS; HUMAN; HYPERTHERMIA; HYPOTENSION; INTENSIVE CARE UNIT; MALIGNANT HYPERTHERMIA; MENTAL DISEASE; MULTIPLE SCLEROSIS; MUSCLE SPASM; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RHABDOMYOLYSIS; SEIZURE; SEROTONIN SYNDROME; SPASTICITY; TACHYCARDIA; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME;

EID: 77953055262     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181dda0d4     Document Type: Article

References (55)

1. Kurz A: Physiology of thermoregulation. Best Pract Res Clin Anaesthesiol 2008; 22: 627-644
2. Benarroch E: Thermoregulation-recent concepts and remaining questions. Neurology 2007; 69:1293-1297
3. Guyton AC, Hall JE: Body temperature, temperature regulation and fever. In: Textbook of Medical Physiology. Ninth Edition. Guyton AC, Hall JE (Eds). Philadelphia, WB Saunders Company, 1996
4. Goldfrank LR, Flomenbaum NE, Lewin NA, et al: Goldfrank's Toxicologic Emergencies. Sixth Edition. Norwalk, CT, Appleton & Lange, 1998
5. O'Grady NP, Barie PS, Bartlett J, et al: Practice parameters for evaluating new fever in critically ill adult patients. Task Force of the American College of Critical Care Medicine of the Society of Critical Care Medicine in collaboration with the Infectious Disease Society of America. Crit Care Med 1998; 26: 392-408
6. Eyer F, Zilker T: Bench to bedside review: Mechanism and management of hyperthermia due to toxicity. Crit Care 2007; 11: 236-243
7. Birmes P, Coppin D, Schmitt L, et al: Serotonin syndrome: A brief review. CMAJ 2003; 168:1439-1442
8. LoCurto MJ: The serotonin syndrome. Emerg Med Clin North Am 1997; 15:665-675
9. Isbister GK, Bowe SJ, Dawson A, et al: Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 2004; 42:227-285
10. Lamb E: Top 200 Drugs of 2008. Available at http://www.pharmacytimes.com. Accessed September 1, 2009
11. Watson WA, Litovitz TL, Rodgers GC Jr, et al: 2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2003; 21:353-421
12. Martin TG: Serotonin syndrome. Ann Emerg Med 1996; 28:520-526
13. Mason PJ, Morris VA: Serotonin syndrome: Presentation of two cases and review of the literature. Medicine 2000; 79:201-209
14. Boyer EW, Shannon M: The serotonin syndrome. N Engl J Med 2005; 352:1112-1120
15. Oates JA, Sjoerdsma A: Neurologic effects of tryptophan in patients receiving monoamine oxidase inhibitor. Neurology 1960; 10: 1076-1078
16. Sternbach H: The serotonin syndrome. Am J Psychiatry 1991; 148:705-713
17. Dunkley EC, Isbister GK, Sibbritt D, et al: The Hunter serotonin toxicity criteria: Simple and accurate diagnostic decision rules for serotonin toxicity. Q J Med 2003; 96:635-642
18. Radomski JW, Dursun SM, Reveley MA, et al. An exploratory approach to the serotonin syndrome: An update of clinical phenomenology and revised diagnostic criteria. Med Hypotheses 2000; 55:218-224
19. Morales N, Vermette H: Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine. Psychosomatics 2005; 46:274-275
20. Douglas AF, Wiener HL, Schwartz DR: Prolonged intrathecal withdrawal syndrome: Case report and discussion of the current therapeutic management: J Neurosurg 2005; 102:1133-1136
21. Hick JL, Smith SW, Lynch MT: Metabolic acidosis in restraint-associated cardiac arrest: A case series. Acad Emerg Med 1999; 6:239-243
22. Bernard S, Buist M, Monteiro O, et al: Induced hypothermia using large volume, icecold intravenous fluid in comatose survivors of out-of-hospital cardiac arrest: A preliminary report. Resuscitation 2003; 56:9-13
23. Graudins A, Stearman A, Chan B: Treatment of the serotonin syndrome with cyproheptadine: J Emerg Med 1998; 16:615-619
24. Brennan D, MacManus M, Howe J, et al: "Neuroleptic malignant syndrome" without neuroleptics. Br J Psychiatry 1998; 152: 578-579
25. Kline SS, Mauro LS, Scala-Barnett DM, et al: Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. Clin Pharmacol 1989; 8:510-514
26. Nisiijima K, Ishiguro T: Does dantrolene influence central dopamine and serotonin metabolism in the neuroleptic malignant syndrome? A retrospective study. Biol Psychiatry 1993; 33: 45-48
27. Ely EW, Shintani A, Truman B, et al: Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA 2004; 291:1753-1762
28. Gurrera RJ, Simpson JC, Tsuang MT: Metaanalytic evidence of systematic bias in estimates of neuroleptic malignant syndrome incidence. Compr Psychiatry 2007; 48: 205-211
29. Atityanjee, Aderibigbe YA, Matthews T: Epidemiology of neuroleptic malignant syndrome. Clin Neuropharmacol 1999; 22: 151-158
30. Shalev A, Hermesh H, Munitz H: Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 1989; 50:18-25
31. Newman EJ, Grosset DG, Kennedy PG: The parkinsonism-hyperpyrexia syndrome. Neurocrit Care 2009; 10:136-140
32. Bhanushali MJ, Tuite PJ: The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin 2004; 22: 389-341
33. Vassallo SU, Delaney KA: Pharmacologic effects on thermoregulation: Mechanisms of drug-related heatstroke. J Toxicol Clin Toxicol 1989; 27:199-224
34. Trollor JN, Chien X, Sachdev PS: Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009; 23: 477-492
35. Assion HJ, Heinemann F, Laux G: Neuroleptic malignant syndrome under treatment with antidepressants? A critical review. Eur Arch Psychiatry Clin Neurosci 1998; 248: 231-239
36. Wetli CV, Mash D, Karch SB: Cocaineassociated agitated delirium and the neuroleptic malignant syndrome. Am J Emerg Med 1996; 14:425-428
37. Velamoor VR, Norman RM, Caroff SN, et al: Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis 1994; 182:168-173
38. Lev R, Clark RF: Neuroleptic malignant syndrome presenting without fever: Case report and review of the literature. J Emerg Med 1994; 12:49-55
39. Bernardi D, Amore M, Keck PE Jr, et al: Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: A casecontrol study. Biol Psychiatry 1998; 44: 748-754
40. Keck PE Jr, Caroff SN, McElroy SL: Neuroleptic malignant syndrome and malignant hyperthermia End of a controversy? J Neuropsychiatry Clin Neurosci 1995; 7:135-144
41. American Psychiatric Association: Neuroleptic malignant syndrome. In: Diagnostic Statistical Manual of Mental Disorders Text Revision. Fourth Edition. Washington, DC, American Psychiatric Association, 2000, Chapter 333.92
42. Levenson J: Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142: 1137-1145
43. Strawn JR, Keck PE, Caroff SN: Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164:870-876
44. Addonizio G, Susman VL, Roth DS: Neuroleptic malignant syndrome: Review and analysis of 115 cases. Biol Psychiatry 1987; 22: 1004-1020
45. Labuda A, Cullen N: Brain injury following neuroleptic malignant syndrome: Case report and review of the literature. Brain Inj 2006; 20:775-778
46. Bellamy CJ, Kane-Gill SL, Falcione BA, et al: Neuroleptic malignant syndrome in traumatic brain injury patients treated with haloperidol. J Trauma 2009; 66: 954-958
47. Rosenberg MR, Green M: Neuroleptic malignant syndrome. Review of response to therapy. Arch Intern Med 1989; 149:1927-1931
48. Rosebush P, Stewart T, Mazurek M: The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care? Br J Psychiatry 1991; 159:709-712
49. Rosenberg H, Davis M, James D, et al: Malignant hyperthermia. Orphanet J Rare Dis 2007; 24; 2:21
50. Ording H, Brancadoro V, Cozzolino S, et al: In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: Results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand 1997; 41:955-966
51. Larach MG: Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group. Anesth Analg 1989; 69:511-515
52. Ali SZ, Taguchi A, Rosenberg H: Malignant hyperthermia. Best Pract Res Clin Anaesthesiol 2003; 17:519-533
53. Saveika JA, Shelton JE: Ciproheptadine for pediatric intrathecal baclofen withdrawal: A case report. Am J Phys Med Rehabil 2007; 86:994-997
54. Meythaler JM, Roper JF, Brunner RC: Cyproheptadine for intrathecal baclofen withdrawal. Arch Phys Med Rehabil 2003; 84: 638-641
55. Ackland GL, Fox R: Low-dose propofol infusion for controlling acute hypertspasticity after withdrawal of intrathecal baclofen therapy. Anesthesiology 2005; 103: 663-665